跳至主要内容
临床试验/EUCTR2009-018049-19-AT
EUCTR2009-018049-19-AT进行中(未招募)不适用

A randomized double blind placebo controlled trial of intranasal submucosal bevacizumab in hereditary hemorrhagic telangiectasia - Bevazizumab in HHT

Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten0 个研究点目标入组 30 人开始时间: 2010年11月23日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
30

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • Diagnosed HHT (Shovlin et al 2000)
  • Minimum of 2 episodes of epistaxis/ week
  • Ability and willigness to complete diary and comply with study requirements
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range

排除标准

  • Uncontrolled hypertension (systolic blood pressure > 150mmHg, diastolic blood pressure > 90mmHg)
  • History of a thromboembolic event, including myocardial infarction or cerebral vascular accident
  • Malignancy of the upper respiratory tract within the last year
  • Recent (<3months) or planned surgery
  • Nasal intervention (Laser or Cautery) in pretreatment phase
  • Allergy to local anaesthetic

研究者

发起方
Medizinische Universität Wien,Univ.Klinik f.Hals-, Nasen- und Ohrenkrankheiten

相似试验